Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Amber Altidor
FDA Greenlights Relacorilant/Nab-Paclitaxel in PROC
The FDA has approved relacorilant (Lifyorli) plus nab-paclitaxel (Abraxane) for the treatment of adult patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (PROC) following 1 to 3 prior lines of systemic therapy including bevacizumab (Avastin).1 The efficacy of the combination was evaluated in the multicenter, open-label phase 3 ROSELLA trial (NCT05257408), which met its overall survival (OS) primary end point in January.2 The major efficacy outcomes were...
The Role of Integrative Medicine in Oncology: Expert Perspectives on Nutrition, Exercise, and Symptom Management
Integrative oncology is increasingly recognized as a vital component of comprehensive cancer care, focusing on the combination of conventional medical treatments with evidence-based complementary therapies to support the whole patient through their cancer journey. In interviews with Oncology Nursing News, experts emphasize that this approach is a collaborative effort to mitigate adverse effects (AEs), improve treatment adherence, and enhance quality of life.
Improving Patient Education on Medication Toxicities in Oncology
Effective oncology education requires tailored communication strategies, such as assessing learning styles and using teach-back methods, to ensure patients understand potential toxicities and feel supported, according to insights from Amber Altidor, NP, at the 23rd American Psychosocial Oncology Society Annual Conference.
Amber Altidor, NP
Articles by Amber Altidor, NP Amber Altidor, NP, shares how oncology nurses can use teach-back methods and learning style assessments to improve patient education on medication toxicities.
Can Anti-Inflammatory Pathway-Targeting Treatment Work in Early Onset CRC?
Research into the distinct pathophysiological drivers of early-onset colorectal cancer (CRC) is a focus of investigation at Columbia University, according to Yoanna S. Pumpalova, MD. Standard genomic analyses have largely demonstrated that the somatic mutation profiles of early onset CRC tumors are genetically similar to those observed in average-onset colorectal cancers, but clinical presentations reveal some differences.
Amber Altidor, NP
Articles by Amber Altidor, NP Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Amber
Contact Amber, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack